322 related articles for article (PubMed ID: 19850678)
1. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.
Filopanti M; Olgiati L; Mantovani G; Corbetta S; Arosio M; Gasco V; De Marinis L; Martini C; Bogazzi F; Cannavò S; Colao A; Ferone D; Arnaldi G; Pigliaru F; Peri A; Angeletti G; Jaffrain-Rea ML; Lania AG; Spada A
J Clin Endocrinol Metab; 2012 Feb; 97(2):E165-72. PubMed ID: 22162472
[TBL] [Abstract][Full Text] [Related]
3. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
4. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly.
Bianchi A; Mazziotti G; Tilaro L; Cimino V; Veltri F; Gaetani E; Pecorini G; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2009; 12(3):196-9. PubMed ID: 19089622
[TBL] [Abstract][Full Text] [Related]
6. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.
Mercado M; González B; Sandoval C; Esquenazi Y; Mier F; Vargas G; de los Monteros AL; Sosa E
J Clin Endocrinol Metab; 2008 Sep; 93(9):3411-5. PubMed ID: 18611972
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients.
de Oliveira Machado E; Lima CH; Ogino LL; Kasuki L; Gadelha MR
Pituitary; 2016 Aug; 19(4):375-80. PubMed ID: 27001494
[TBL] [Abstract][Full Text] [Related]
9. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
12. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
13. GH receptor isoforms and skeletal fragility in acromegaly.
Mormando M; Nasto LA; Bianchi A; Mazziotti G; Giampietro A; Pola E; Pontecorvi A; Giustina A; De Marinis L
Eur J Endocrinol; 2014 Aug; 171(2):237-45. PubMed ID: 24866575
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
[TBL] [Abstract][Full Text] [Related]
15. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome.
Bernabeu I; Marazuela M; Lucas T; Loidi L; Alvarez-Escolá C; Luque-Ramírez M; Fernandez-Rodriguez E; Paniagua AE; Quinteiro C; Casanueva FF
J Clin Endocrinol Metab; 2010 May; 95(5):2147-54. PubMed ID: 20207827
[TBL] [Abstract][Full Text] [Related]
16. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
18. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
Montefusco L; Filopanti M; Ronchi CL; Olgiati L; La-Porta C; Losa M; Epaminonda P; Coletti F; Beck-Peccoz P; Spada A; Lania AG; Arosio M
Clin Endocrinol (Oxf); 2010 May; 72(5):661-7. PubMed ID: 20447065
[TBL] [Abstract][Full Text] [Related]
19. The exon 3-deleted growth hormone receptor: molecular and functional characterization and impact on GH/IGF-I axis in physiological and pathological conditions.
Filopanti M; Giavoli C; Grottoli S; Bianchi A; De Marinis L; Ghigo E; Spada A
J Endocrinol Invest; 2011 Dec; 34(11):861-8. PubMed ID: 22322534
[TBL] [Abstract][Full Text] [Related]
20. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
